Skip to content Skip to navigation

Pharmaceuticals

Box of Zantac

This complaint concerns a drug brand-named Zantac, and names as defendants maker Sanofi US, LLC, distributor Chattem, Inc., and sellers CVS Health Co. (formerly CVS Caremark) and Dollar Tree Stores, Inc. The complaint alleges that the drug contains “dangerously high levels or N-nitrosodimethylamine (NDMA).

Anda Logo with Panda

This complaint against another company that deals in opioids takes a different tack than most. The complaint claims that Anda, Inc., a distributor, through its careless handling of the drugs, has caused health insurance costs to go up.

Bottle of Revlimid Pills

Celgene Corporation is paying $55 million to settle antitrust class actions about its drugs Thalomid and Revlimid. The complaints alleged that the company acted to keep generics of the drugs off the market for a time, forcing consumers to pay more for the drugs than they would have with open market competition.

Santarus Glumetza Label

What’s a fair price for a thirty-day supply of the extended-release diabetes medicine Glumetza—generic name metformin? Is it $55 or $2,200? The complaint for this class action alleges that a number of companies conspired to limit the entry of generic versions of Glumetza to the market. The defendants in this antitrust suit are Bausch Health Compaines, Inc. (formerly Valeant Pharmaceuticals International), Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Santarus, Inc., Assertio Therapeutics, Inc. (formerly Depomed, Inc.), Lupin Pharmaceuticals, Inc., and Lupin, Ltd.

Zytiga Box and Bottle

Patents are a tricky topic. They take years to acquire; they expire eventually; and even after they are acquired, they can be declared invalid. The last two points are the concern of this class action against Janssen Biotech, Inc., two other Janssen companies, and partner BTG International Limited. The complaint argues that when the patent on their very lucrative drug Zytiga expired, the companies kept generic competitors at bay with an invalid patent, thus requiring consumers and insurers to pay more for the drug than they would have if generics had been allowed on the market.

Two Pills on Counter with Prescription Bottles Behind

When the patents for drugs expires, competitor companies may create biosimilars or generics. Biosimilars and generics are supposed to be the equal of brand-name drugs. The FDA says, “All generic drugs approved by FDA have the same high quality, strength, purity, and stability as brand-name drugs.” However, the complaint for this class action alleges that Torrent Pharma, Inc. sold contaminated generics to consumers. The medication at issue is losartan and combinations containing losartan. 

Box and Bottle for Zytiga

This class action presents a familiar story: a group of pharmaceutical companies—Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC, and BTG International Limited—unfairly prevented generics of a profitable drug  (Zytiga) from entering the market, thus costing consumers and health insurers more than they should have paid. However, at issue here are not payoffs and illicit agreements but patents and their validity.

Box of Humira

This is another antitrust class action against AbbVie and other companies, filed just ten days after the first, for anticompetitive behavior in relation to AbbVie’s drug Humira. The complaint alleges that AbbVie tried to maintain its monopoly on the drug by making illegal arrangements with companies that might have brought out biosimilars, thereby keeping the price of the drug artificially high.

Prescription Bottles and Pills

A massive pharmaceutical case is building in the federal court system involving the drugs Dexilant, Nexium, Prevacid, Prilosec, and Protonix. Although the master complaint does not seem to be available at the moment, some clues are evident from a First Amended Short Form Complaint in one of the many cases joining this action.

Aurobindo Drug Facility

A number of cases have already been brought on the same allegations as this one: that lots of a drug called valsartan were sold in the US despite being contaminated with a substance called NDEA. The complaint in this case brings suit against Aurobindo Pharma USA, Inc. and Aurobindo Pharma Ltd., a maker of the drug located in India. 

Pages